The Consistency Project
on the Magic Pill Myth: Understanding the Limitations of GLP-1 Weight Loss Drugs
/
RSS Feed
We return to the topic of the weight loss drug semaglutide, sold under brand names such as Wegovy and Ozempic. We explore who these drugs are suitable for, what to expect when starting this type of therapy, and how they fit into the broader context of health management.
Topics include:
- The indications and potential candidates for GLP-1 weight loss drugs
- Expected results and side effects of semaglutide therapy
- The role of diet and exercise in conjunction with GLP-1 drugs
- Strategies for maintaining weight loss after discontinuing the medication
- The long-term effects and safety considerations of GLP-1 drugs
Referenced Articles
Bikou et al., 2024. Lean mass loss and semaglutide.
Kompaniyets et al., 2023. Probability of 5% weight loss.
Lincoff et al., 2023. Semaglutide and cardiovascular events.
Nagendra et al., 2023. Semaglutide and cancer risk.
Rubino et al., 2021. Semaglutide clinical trial where participants regained weight after they went off the drug.
Wilding et al., 2021. Semaglutide and weight regain.
Referenced Podcast
On the Weight Loss Drug That… Works?